{
  "abstract": "Production of glucagon-like peptide-1 receptor (GLP-1) agonists such as semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) needs to be rapidly expanded and prices reduced, the World Health Organization (WHO) has said in new guidance.",
  "authors": [
    {
      "affiliations": [
        "Rio de Janeiro"
      ],
      "name": "Luke Taylor"
    }
  ],
  "title": "WHO: Ramp up production of weight loss injections to combat global obesity",
  "uid": "7703cd2f-744f-51a0-a4ef-f9f3e0a9bd74"
}